Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Moodys
McKinsey
Boehringer Ingelheim
Mallinckrodt

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYZAAR

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Hyzaar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00234858 Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) Completed Abbott Phase 4 2004-03-01 The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome
NCT00274638 PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM) Completed Boehringer Ingelheim Phase 4 2002-07-01 To demonstrate that Telmisartan combined with Hydrochlorothiazide (MICARDIS® HCT) is superior to Losartan with Hydrochlorothiazide (Hyzaar®) in lowering blood pressure in mild-moderate hypertensives.
NCT00354991 Hyzaar Asia HEAALTH (0954A-950) Completed Merck Sharp & Dohme Corp. Phase 3 2006-06-01 The objective of the study is to estimate the percentage of patients who reach blood pressure goal after 8 weeks of treatment with losartan/HCTZ combination.
NCT00398541 Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322) Completed Merck Sharp & Dohme Corp. Phase 3 2005-03-01 Evaluate the antihypertensive and neuroprotective effects of Hyzaar(R) in elderly subjects in comparison with Natrilix(TM).
NCT00400218 Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) Completed Merck Sharp & Dohme Corp. Phase 3 2005-09-01 Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.
NCT00480805 HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2002-10-01 A study to test the safety and efficacy of HYZAAR as compared to Ramipril in patients with type 2 diabetes mellitus (high blood sugar) and hypertension (high blood pressure).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hyzaar

Condition Name

Condition Name for Hyzaar
Intervention Trials
Hypertension 8
Healthy 4
Fasting 1
Essential Arterial Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hyzaar
Intervention Trials
Hypertension 7
Syndrome 1
Metabolic Syndrome X 1
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hyzaar

Trials by Country

Trials by Country for Hyzaar
Location Trials
United States 29
India 1
France 1
Jordan 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hyzaar
Location Trials
Georgia 2
North Dakota 2
New Mexico 1
New York 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hyzaar

Clinical Trial Phase

Clinical Trial Phase for Hyzaar
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 1 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hyzaar
Clinical Trial Phase Trials
Completed 11
Unknown status 2
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hyzaar

Sponsor Name

Sponsor Name for Hyzaar
Sponsor Trials
Merck Sharp & Dohme Corp. 4
EMS 2
Torrent Pharmaceuticals Limited 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hyzaar
Sponsor Trials
Industry 14
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKinsey
Boehringer Ingelheim
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.